The Effects of Antidepressants on the Results of Skin Prick Tests Used in the Diagnosis of Allergic DiseasesIsik S.R.a · Celikel S.a · Karakaya G.a · Ulug B.b · Kalyoncu A.F.a
aDepartment of Chest Diseases, Adult Allergy Unit and bDepartment of Psychiatry, School of Medicine, Hacettepe University, Ankara, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Some drugs may cause false negative results by suppressing the reactivity of the skin prick tests (SPTs). The aim of this survey was to show whether escitalopram, fluoxetine and sertraline had any effect on the reactivity of SPT. Methods: Twenty-four patients who were admitted to the outpatient clinic of the Psychiatry Department at the Hacettepe University Hospital and planned to be treated by these antidepressants were included in the study between May and October 2008. SPTs with positive control (histamine), negative control and 3 common aeroallergens were performed in the beginning, at the first and fourth weeks. A questionnaire including 26 questions about respiratory symptoms and allergic diseases was filled in face to face by the fellow-in-training. The Visual Analog Scale (VAS) of current respiratory and nasal symptoms was recorded at all 3 visits. Results: There were no statistically significant differences between the 3 mean diameters measured at 3 time points in addition to the mean diameters of the wheals between groups using escitalopram, sertraline and fluoxetine (p > 0.05). There was a statistically significant decrease between the VAS of nasal symptoms at the 3 visits (p < 0.05). Conclusions: Escitalopram, fluoxetine and sertraline do not seem to affect the reactivity of SPTs. Nasal symptoms might have been decreased due to both the allergic treatment suggested and the end of the pollen season.
© 2010 S. Karger AG, Basel
Averbeck M, Gebhardt C, Emmrich F, Treudler R, Simon JC: Immunologic principles of allergic disease. J Dtsch Dermatol Ges 2007;1015–1028.
Kay AB: Allergy and allergic diseases. N Engl J Med 2001;344:33–37.
Demoly P, Piette V, Bousquet J: In vivo methods for study of allergy skin tests, techniques, and interpretation; in Middleton EJ, Reed CE, Ellis Ef, Adkinson NF Jr, Yunginger JW, Buse W (eds): Allergy: Principles and Practice, ed 5. St. Louis, Mosby Year Book, 2003, pp 631–642.
Dreborg S: Methods for skin testing. Allergy 1989;44(suppl 10):22–30.
- Nelson HS: Variables in allergy skin testing. Allergy Proc 1994;15:265–268.
- Bordignon V, Burastero SE: Age, gender and reactivity to allergens independently influence skin reactivity to histamine. J Investig Allergol Clin Immunol 2006;16:129–135.
- Li JT: Allergy testing. Am Fam Physician 2002;66:621–624.
- Rao KS, Menon PK, Hilman BC, Sebastian CS, Bairnsfather L: Duration of the supressive effect of tricyclic antidepressants on histamine induced wheal and flare reactions in human skin. J Allergy Clin Immunol 1988;82:752–757.
- Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psycopharmacol 1996;11(suppl 1):5–11.
- Gupta MA, Gupta AK: The use of antidepressant drugs in dermatology. J Eur Acad Derm and Vener 2001;15:512–518.
- Carrasco JL, Sandner C: Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005;59:1228–1234.
- Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-Fluoxetine. Biol Psychiatry 2001;50:345–350.
- Wewers ME, Lowe NK: A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990;13:227–236.
Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 1993;48(14 suppl):48–82.
- Jutel M, Blaser K, Akdis CA: Histamine in chronic allergic responses. J Invest Allergol Clin Immunol 2005;15:1–8.
- Almind M, Dirksen A, Nielsen NH, Svendson UG: Duration of the inhibitory activity of histamine-induced skin wheals of sedative and non-sedative antihistamines. Allergy 1988;43:593–596.
- Sullivan TJ: Pharmacologic modulation of the whealing response to histamine in human skin: identification of doxepine as a potent in vivo inhibitor. J Allergy Clin Immunol 1982;69:260–267.
- Kupczyk M, Kupryś I, Bocheńska-Marciniak M, Górski P, Kuna P: Ranitidine (150 mg daily) inhibits wheal, flare, and itching reactions in skin-prick tests. Allergy Asthma Proc 2007;28:711–715.
- Kupczyk M, Kupryś I, Górski P, Kuna P: The effect of montelukast (10mg daily) and loratadine (10 mg daily) on wheal, flare and itching reactions in skin prick tests. Pulm Pharmacol and Ther 2007;20:85–89.
- Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS, Blanco C: Gender differences in generalized anxiety disorder: results from the national epidemiologic survey on alcohol and related conditions (NESARC). J Clin Psychiatry 2008;69:1606–1616.
- Regitz-Zagrosek V, Schubert C, Krüger S: Gender differences in psychopharmacology. Internist (Berl) 2008;49:1516–1519.
- Chen W, Mempel M, Schober W, Behrendt H, Ring J: Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008;68:1418–1427.
- Price DD, McGrath PA, Rafii A, Buckingham B: The validation of visual analog scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45–56.
- Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT, El-Akkad T: Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733–741.
- Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Méchin H, Daures JP, Bousquet J: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007;62:367–372.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.